Cargando…

Short and Long-Term Effects of Telaprevir on Kidney Function in Patients with Hepatitis C Virus Infection: A Retrospective Cohort Study

BACKGROUND: Recent reports suggest that telaprevir, a protease inhibitor used to treat hepatitis C infection, is associated with decline in kidney function during therapy, particularly in patients with baseline renal impairment. METHODS: Patients treated with telaprevir in a single healthcare networ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sise, Meghan E., Backman, Elke S., Wenger, Julia B., Wood, Brian R., Sax, Paul E., Chung, Raymond T., Thadhani, Ravi, Kim, Arthur Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414554/ https://www.ncbi.nlm.nih.gov/pubmed/25923243 http://dx.doi.org/10.1371/journal.pone.0124139

Ejemplares similares

Telaprevir
Publicado: (2012)

Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C
por: Brogan, Anita J., et al.
Publicado: (2014)

Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
por: Gomes, Lenyta Oliveira, et al.
Publicado: (2018)

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

Safety and Efficacy of Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir for Hepatitis C Virus Infection Across All Levels of Kidney Function
por: Sise, Meghan E.
Publicado: (2018)

Cutaneous Eruption due to Telaprevir
por: Falcão, Eduardo Mastrangelo Marinho, et al.
Publicado: (2015)

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir
por: Johnson, Mark, et al.
Publicado: (2014)

Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir
por: D’Ambrosio, Roberta, et al.
Publicado: (2012)

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
por: Karino, Y, et al.
Publicado: (2014)

Telaprevir Experience From Turkey
por: Komur, Suheyla, et al.
Publicado: (2015)

Telaprevir or boceprevir for hepatitis C treatment: a first survey on pharmacoutilization
por: Capuozzo, Maurizio, et al.
Publicado: (2013)

Comment to “Telaprevir Experience From Turkey”
por: Akar, Tarik, et al.
Publicado: (2015)

Chronic Hepatitis C Therapy in Liver Cirrhosis Complicated by Telaprevir-Induced DRESS
por: Mousa, Omar Y. S., et al.
Publicado: (2014)

Formulary Management of the Protease Inhibitors Boceprevir and Telaprevir for Chronic Hepatitis C Virus
por: Tungol, Alexandra, et al.
Publicado: (2011)

Low Complement C4 Predicts Improvement of Kidney Function After Direct‐Acting Antiviral Therapy for Hepatitis C Virus
por: Sise, Meghan E., et al.
Publicado: (2020)

Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study
por: Allegretti, Andrew S., et al.
Publicado: (2015)

Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection
por: Thorlund, Kristian, et al.
Publicado: (2012)

Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir
por: De Meyer, Sandra, et al.
Publicado: (2014)

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
por: Colombo, M, et al.
Publicado: (2014)

Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C
por: Kondo, C, et al.
Publicado: (2016)

Impact of Specialty Pharmacy on Telaprevir-Containing 3-Drug Hepatitis C Regimen Persistence
por: Henderson, Rochelle R., et al.
Publicado: (2014)

Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2013)

Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C
por: Yamagiwa, Satoshi, et al.
Publicado: (2017)

Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection
por: Bichoupan, Kian, et al.
Publicado: (2017)

Telaprevir-Induced DRESS Syndrome Associated With Salmonella typhi
por: Akar, Tarık, et al.
Publicado: (2015)

Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study
por: Flamm, Steven L., et al.
Publicado: (2014)

Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfected patients are comparable with hepatitis C monoinfected patients
por: O’Neil, Conar R, et al.
Publicado: (2015)

Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis
por: Cooper, Curtis L, et al.
Publicado: (2012)

Evaluation of Persistence of Resistant Variants with Ultra-Deep Pyrosequencing in Chronic Hepatitis C Patients Treated with Telaprevir
por: Thomas, Xiomara V., et al.
Publicado: (2012)

Efficacy and Tolerability of Telaprevir for Chronic Hepatitis Virus C Genotype 1 Infection: A Meta-Analysis
por: Kong, Yuan, et al.
Publicado: (2012)

Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C–Viremic Donor to Uninfected Recipient Kidney Transplantation
por: Sise, Meghan E., et al.
Publicado: (2020)

Modeling Viral Evolutionary Dynamics after Telaprevir-Based Treatment
por: Haseltine, Eric L., et al.
Publicado: (2014)

Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management
por: Seethapathy, Harish, et al.
Publicado: (2021)

Feasibility of Telaprevir-Based Triple Therapy in Liver Transplant Patients with Hepatitis C Virus: SVR 24 Results
por: Werner, Christoph R., et al.
Publicado: (2013)

Anti-rods/rings autoantibody seropositivity does not affect response to telaprevir treatment for chronic hepatitis C infection
por: Calise, S. John, et al.
Publicado: (2016)

Pharmacokinetic characteristics of telaprevir in healthy Korean male subjects and comparisons with Japanese
por: Choi, Yewon, et al.
Publicado: (2018)

Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection
por: Yamada, I, et al.
Publicado: (2012)

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C
por: Hayashi, N, et al.
Publicado: (2012)

Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy
por: Neukam, Karin, et al.
Publicado: (2015)

Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection
por: Lin, Ming V., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ooggrlpri7kkjq0eb3cho7dd1k